Literature DB >> 24030742

B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease.

Jesse M Jaso1, C Cameron Yin1, Victoria W Lu1, Ming Zhao1, Lynne V Abruzzo1, M James You1, Yaling Yang1, Raja Luthra1, L Jeffrey Medeiros1, Gary Lu1.   

Abstract

B acute lymphoblastic leukemia (B-ALL) with t(14;19)(q32;p13.1), in which IGH and EPOR are juxtaposed, has been reported rarely. We describe the clinicopathological features of six patients, three men and three women, with a median age of 39 years. Initial and follow-up bone marrow samples were examined from each patient. The clinical, morphologic, and immunophenotypic results were compared with data obtained from conventional cytogenetic analysis and by using home-brew fluorescence in situ hybridization (FISH) probes for IGH at 14q32 and EPOR at 19p13.1. The bone marrow specimens were hypercellular (median 90%; range 80-100%), with a median blast count of 90% (range 60-93%). Immunophenotypic analysis performed by flow cytometry demonstrated a stable, precursor B-cell immunophenotype. The t(14;19)(q32;p13.1) was present in all cases with morphologic evidence of disease. The translocation was stable and appeared morphologically subtle on conventional karyotypic analysis. Detection was facilitated using FISH, which confirmed IGH/EPOR rearrangement in all cases. All patients received aggressive multiagent chemotherapy as part of a variety of regimens. Four of six patients achieved an initial complete remission, but all relapsed. At last follow-up, five of six patients had died of disease (median survival, 12 months after diagnosis). We conclude that B-ALL associated with t(14;19)(q32;p13.1) is a distinctive form of disease that is associated with younger patient age and an aggressive clinical course.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030742     DOI: 10.1038/modpathol.2013.149

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  4 in total

1.  ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.

Authors:  L Falchi; M Mehrotra; K J Newberry; L M Lyle; G Lu; K P Patel; R Luthra; U Popat; S Verstovsek
Journal:  Leukemia       Date:  2014-05-23       Impact factor: 11.528

Review 2.  Childhood B-acute lymphoblastic leukemia: a genetic update.

Authors:  Jennifer S Woo; Michael O Alberti; Carlos A Tirado
Journal:  Exp Hematol Oncol       Date:  2014-06-13

3.  [Ph-like acute lymphocytic leukemia with EPOR rearrangement: 2 cases report and literatures review].

Authors:  Q Yang; H G Shao; H F Liu; S X Bai; J Zhang; Y Wang; J Shen; C X Wu; H Y Qiu; S N Chen; J L Pan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-09-14

Review 4.  How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Avraham Frisch; Yishai Ofran
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.